{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:07:52Z","timestamp":1780531672465,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":51,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Capes, CNPq, Faperj"},{"DOI":"10.13039\/501100004586","name":"Faperj","doi-asserted-by":"crossref","award":["Pos Doc Fellowship"],"award-info":[{"award-number":["Pos Doc Fellowship"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004586","name":"Faperj","doi-asserted-by":"crossref","award":["PhD Fellowship"],"award-info":[{"award-number":["PhD Fellowship"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-48524-0","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T07:50:03Z","timestamp":1776153003000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Correlation between neuropathy severity and neurofilament light chain levels in Brazilian patients with hereditary transthyretin amyloidosis"],"prefix":"10.1038","volume":"16","author":[{"given":"Priscila","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"do Amaral Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Araujo Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreza","family":"Salvio Lemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soniza","family":"Vieira Alves-Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Foguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Waddington Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"issue":"5","key":"48524_CR1","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/mus.26034","volume":"57","author":"HH Schmidt","year":"2018","unstructured":"Schmidt, H. H. et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve 57(5), 829\u2013837. https:\/\/doi.org\/10.1002\/mus.26034 (2018).","journal-title":"Muscle Nerve"},{"issue":"2","key":"48524_CR2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10072-020-04889-2","volume":"43","author":"F Manganelli","year":"2022","unstructured":"Manganelli, F. et al. Hereditary transthyretin amyloidosis overview. Neurol. Sci. 43(2), 595\u2013604. https:\/\/doi.org\/10.1007\/s10072-020-04889-2 (2022).","journal-title":"Neurol. Sci."},{"issue":"12","key":"48524_CR3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50527","volume":"15","author":"ME Kaiser","year":"2023","unstructured":"Kaiser, M. E. & Lewis, T. A. J. Heart of the matter: Decoding the underdiagnosed cardiac amyloidosis. Cureus 15(12), 50527. https:\/\/doi.org\/10.7759\/cureus.50527 (2023).","journal-title":"Cureus"},{"key":"48524_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/17539447231216318","volume":"1","author":"CS Kwok","year":"2023","unstructured":"Kwok, C. S. & Moody, W. E. The importance of pathways to facilitate early diagnosis and treatment of patients with cardiac amyloidosis. Ther. Adv. Cardiovasc. Dis. 1, 17. https:\/\/doi.org\/10.1177\/17539447231216318 (2023).","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"issue":"1","key":"48524_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1000-1","volume":"14","author":"M Waddington-Cruz","year":"2019","unstructured":"Waddington-Cruz, M. et al. Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: A global case series. Orphanet J. Rare Dis. 14(1), 8. https:\/\/doi.org\/10.1186\/s13023-019-1000-1 (2019).","journal-title":"Orphanet J. Rare Dis."},{"issue":"7","key":"48524_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","volume":"15","author":"D Adams","year":"2019","unstructured":"Adams, D., Koike, H., Slama, M. & Coelho, T. Hereditary transthyretin amyloidosis: A model of medical progress for a fatal disease. Nat. Rev. Neurol. 15(7), 387\u2013404. https:\/\/doi.org\/10.1038\/s41582-019-0210-4 (2019).","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"48524_CR7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/s0002-9343(98)00037-0","volume":"104","author":"S Vincent Rajkumar","year":"1998","unstructured":"Vincent Rajkumar, S., Gertz, M. A. & Kyle, R. A. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am. J. Med. 104(3), 232\u2013237. https:\/\/doi.org\/10.1016\/s0002-9343(98)00037-0 (1998).","journal-title":"Am. J. Med."},{"issue":"9","key":"48524_CR8","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1007\/s00415-020-09899-w","volume":"267","author":"B Vogt","year":"2020","unstructured":"Vogt, B., Chahin, N., Wiszniewski, W., Ragole, T. & Karam, C. Screening for genetic mutations in patients with neuropathy without definite etiology is useful. J. Neurol. 267(9), 2648\u20132654. https:\/\/doi.org\/10.1007\/s00415-020-09899-w (2020).","journal-title":"J. Neurol."},{"issue":"6","key":"48524_CR9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.62981","volume":"16","author":"P Dave","year":"2024","unstructured":"Dave, P. et al. RNA interference therapeutics for hereditary amyloidosis: A narrative review of clinical trial outcomes and future directions. Cureus 16(6), 62981. https:\/\/doi.org\/10.7759\/cureus.62981 (2024).","journal-title":"Cureus"},{"key":"48524_CR10","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-1781463","author":"M Dias","year":"2024","unstructured":"Dias, M. et al. Real-life experience with inotersen at CEPARM, Hospital Universit\u00e1rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro. Arq. Neuropsiquiatr. https:\/\/doi.org\/10.1055\/s-0044-1781463 (2024).","journal-title":"Arq. Neuropsiquiatr."},{"issue":"3","key":"48524_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.hfc.2024.03.007","volume":"20","author":"TM Capovilla","year":"2024","unstructured":"Capovilla, T. M. et al. Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones. Heart Fail Clin. 20(3), 333\u2013341. https:\/\/doi.org\/10.1016\/j.hfc.2024.03.007 (2024).","journal-title":"Heart Fail Clin."},{"issue":"4","key":"48524_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/jns.12519","volume":"27","author":"TH Brannagan","year":"2022","unstructured":"Brannagan, T. H. et al. Liver-directed drugs for transthyretin-mediated amyloidosis. J. Peripher. Nerv. Syst. 27(4), 228\u2013237. https:\/\/doi.org\/10.1111\/jns.12519 (2022).","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"9","key":"48524_CR13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2016072118","volume":"118","author":"X Jiang","year":"2021","unstructured":"Jiang, X. et al. A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction. Proc. Natl. Acad. Sci. U. S. A. 118(9), 2016072118. https:\/\/doi.org\/10.1073\/pnas.2016072118 (2021).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"48524_CR14","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/j.bpj.2020.08.043","volume":"119","author":"MC Childers","year":"2020","unstructured":"Childers, M. C. & Daggett, V. Edge strand dissociation and conformational changes in transthyretin under amyloidogenic conditions. Biophys. J. 119(10), 1995\u20132009 (2020).","journal-title":"Biophys. J."},{"issue":"10","key":"48524_CR15","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1016\/j.bpj.2020.08.043","volume":"84","author":"PN Hoffman","year":"2020","unstructured":"Hoffman, P. N. et al. Neurofilament gene expression: a major determinant of axonal caliber. Proc Natl Acad Sci U S A. 84(10), 3472. https:\/\/doi.org\/10.1016\/j.bpj.2020.08.043 (2020).","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"48524_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s0006-8993(03)03219-0","volume":"987","author":"N Norgren","year":"2003","unstructured":"Norgren, N., Rosengren, L. & Stigbrand, T. Elevated neurofilament levels in neurological diseases. Brain Res. 987(1), 25\u201331. https:\/\/doi.org\/10.1016\/s0006-8993(03)03219-0 (2003).","journal-title":"Brain Res."},{"issue":"21","key":"48524_CR17","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1212\/WNL.0000000000001015","volume":"83","author":"T Skillb\u00e4ck","year":"2014","unstructured":"Skillb\u00e4ck, T. et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology 83(21), 1945\u20131953. https:\/\/doi.org\/10.1212\/WNL.0000000000001015 (2014).","journal-title":"Neurology"},{"issue":"3","key":"48524_CR18","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jamaneurol.2018.3746.","volume":"76","author":"B Olsson","year":"2019","unstructured":"Olsson, B. et al. Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders. JAMA Neurol. 76(3), 318\u2013325. https:\/\/doi.org\/10.1001\/jamaneurol.2018.3746. (2019).","journal-title":"JAMA Neurol."},{"issue":"2","key":"48524_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/mus.23901","volume":"49","author":"I Concei\u00e7\u00e3o","year":"2014","unstructured":"Concei\u00e7\u00e3o, I., Costa, J., Castro, J. & de Carvalho, M. Neurophysiological techniques to detect early small-fiber dysfunction in transthyretin amyloid polyneuropathy. Muscle Nerve 49(2), 181\u2013186. https:\/\/doi.org\/10.1002\/mus.23901 (2014).","journal-title":"Muscle Nerve"},{"issue":"1","key":"48524_CR20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/13506129.2020.1815696","volume":"28","author":"J Louwsma","year":"2021","unstructured":"Louwsma, J. et al. Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis. Amyloid 28(1), 50\u201355. https:\/\/doi.org\/10.1080\/13506129.2020.1815696 (2021).","journal-title":"Amyloid"},{"issue":"3","key":"48524_CR21","doi-asserted-by":"publisher","first-page":"E412","DOI":"10.1212\/WNL.0000000000011090","volume":"96","author":"S Ticau","year":"2021","unstructured":"Ticau, S. et al. Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis. Neurology 96(3), E412\u2013E422. https:\/\/doi.org\/10.1212\/WNL.0000000000011090 (2021).","journal-title":"Neurology"},{"issue":"2","key":"48524_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/13506129.2019.1708716","volume":"27","author":"LF Maia","year":"2020","unstructured":"Maia, L. F. et al. Plasma neurofilament light chain: An early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid 27(2), 97\u2013102. https:\/\/doi.org\/10.1080\/13506129.2019.1708716 (2020).","journal-title":"Amyloid"},{"issue":"4","key":"48524_CR23","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/jns.12350","volume":"24","author":"M Kapoor","year":"2019","unstructured":"Kapoor, M. et al. Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. J. Peripher. Nerv. Syst. 24(4), 314\u2013319. https:\/\/doi.org\/10.1111\/jns.12350 (2019).","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"2","key":"48524_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/13506129.2024.2313218","volume":"31","author":"AS Carroll","year":"2024","unstructured":"Carroll, A. S. et al. Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice. Amyloid 31(2), 95\u2013104. https:\/\/doi.org\/10.1080\/13506129.2024.2313218 (2024).","journal-title":"Amyloid"},{"issue":"1","key":"48524_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000052074","volume":"41","author":"V Bril","year":"1999","unstructured":"Bril, V. NIS-LL: The primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. Eur. Neurol. 41(1), 8\u201313 (1999).","journal-title":"Eur. Neurol."},{"issue":"8(1)","key":"48524_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12289","volume":"5","author":"EL Robertson","year":"2022","unstructured":"Robertson, E. L. et al. Characterization of cerebrospinal fluid biomarkers associated with neurodegenerative diseases in healthy cynomolgus and rhesus macaque monkeys. Alzheimers Dement (N Y) 5(8(1)), e12289. https:\/\/doi.org\/10.1002\/trc2.12289 (2022).","journal-title":"Alzheimers Dement (N Y)"},{"issue":"41(Suppl. 1)","key":"48524_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000052074","volume":"1","author":"V Bril","year":"1999","unstructured":"Bril, V. The primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. Eur. Neurol. 1(41(Suppl. 1)), 8\u201313. https:\/\/doi.org\/10.1159\/000052074 (1999) (NIS-LL:).","journal-title":"Eur. Neurol."},{"issue":"1","key":"48524_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/17482968.2011.627589","volume":"13","author":"M Otto","year":"2012","unstructured":"Otto, M. et al. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph. Lateral Scler. 13(1), 1\u201310. https:\/\/doi.org\/10.3109\/17482968.2011.627589 (2012).","journal-title":"Amyotroph. Lateral Scler."},{"issue":"3","key":"48524_CR29","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","volume":"21","author":"P Benkert","year":"2022","unstructured":"Benkert, P. et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: A retrospective modelling and validation study. Lancet. Neurol. 21(3), 246\u2013257. https:\/\/doi.org\/10.1016\/S1474-4422(22)00009-6 (2022).","journal-title":"Lancet. Neurol."},{"issue":"2","key":"48524_CR30","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1080\/13506129.2024.2327342","volume":"31","author":"M Berendsa","year":"2024","unstructured":"Berendsa, M. et al. Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis. Amyloid 31(2), 132\u2013141. https:\/\/doi.org\/10.1080\/13506129.2024.2327342 (2024).","journal-title":"Amyloid"},{"key":"48524_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1660344","volume":"16","author":"\u00c1 Gragera-Mart\u00ednez","year":"2025","unstructured":"Gragera-Mart\u00ednez, \u00c1. et al. Clinical utility of neurofilament light chain as a biomarker for disease onset and progression in hereditary transthyretin amyloidosis. Front. Neurol. 16, 1660344. https:\/\/doi.org\/10.3389\/fneur.2025.1660344 (2025).","journal-title":"Front. Neurol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48524-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48524-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48524-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T23:44:41Z","timestamp":1780530281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48524-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["48524"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-48524-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The study was approved by the Ethics Committee of Clementino Fraga Filho University Hospital (CAAE: 03102012.4.1001.5257) in accordance with the provisions of the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"17280"}}